Allogeneic bone marrow transplantation for malignant hematologic disorders in children

Area of Science:

• Hematology
• Pediatric Oncology
• Transplantation Immunology

Background:

• Leukemia in children with high-risk prognostic factors presents a significant therapeutic challenge.
• Allogeneic bone marrow transplantation (BMT) is a potential curative option for these patients.
• Managing post-transplant complications like granulocytopenia is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of allogeneic BMT in pediatric leukemia patients with high-risk factors.
• To assess the impact of recombinant granulocyte colony-stimulating factor (rG-CSF) on granulocytopenia recovery post-BMT.

Main Methods:

• Allogeneic bone marrow transplantation (BMT) was performed on 14 pediatric leukemia patients.
• Patients included diagnoses of acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS).
• Recombinant granulocyte colony-stimulating factor (rG-CSF) was administered to six patients to shorten the period of granulocytopenia.

Main Results:

• Survival in complete remission was observed in 10 out of 14 patients (8 to 58 months post-BMT).
• Relapse and chronic graft-versus-host disease (GVHD) were causes of mortality in four patients.
• The mean recovery time to a granulocyte count of 500/mm³ was 13.2 days in the rG-CSF group, significantly faster than in the control group.

Conclusions:

• Allogeneic BMT is a feasible and potentially life-saving treatment for pediatric leukemia patients with high-risk prognostic factors.
• rG-CSF demonstrates effectiveness in accelerating neutrophil recovery, potentially reducing infection risk following BMT.
• Further research into optimizing BMT protocols and supportive care, including growth factors, is warranted.